Comment on: ALBAN (GETUG-AFU 37): a phase III, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC) - Contieri, R.; Mollica, V.; Shariat, S.F.; Pradere, B. (Annals of Oncology, 2026)